NOMURA FINANCIAL PRODUCTS EUROPE GMBH
Location
MILANO
Founded
2018-12-12
Website
Risk Signals
1247 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Miscellaneous business Credit Institutions), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about NOMURA FINANCIAL PRODUCTS EUROPE GMBH
Live alerts from global media, monitored by Business Radar
2025-05-30 (longportapp.com)
Nomura: Gives CSPC PHARMA a target price of HKD 8.02 with a rating of "Buy"
Nomura released a research report stating that it has set a target price of HKD 8.02 for CSPC PHARMA, with a rating of "Buy." The report indicates that CSPC PHARMA's performance in the first quarter of 2025 was weak, with revenue decreasing by 21.9% year-on-year to RMB 7 billion (the same below), lower than the expected RMB 8.8 billion, and profit decreasing by 8.4% year-on-year to RMB 1.5 billion, also below the expected RMB 2.4 billion. The gross profit margin decreased by 5.2 percentage points year-on-year to 67.1%, with the gross profit margin for pharmaceutical sales being lower than the firm's expectations, mainly due to adverse changes in the product mix
Read more
2025-05-29 (ndtvprofit.com)
Sansera Engineering Q4 Review: Price Target Cut By Nomura As Exports Weaken
Sansera Engineering had its target price reduced from Rs 1,669 to Rs 1,643 per share by Nomura amid possible tailwinds from US trade tariffs. The research firm maintained its 'buy' stance on the company as fourth quarter margins were in line with its estimates. Ebitda margin was at 16.3%, in line with Nomura's estimate but lower than consensus estimate of 17.2%. Profit After Tax increased 28% on lower interest expense and higher other income.
Read more
2025-05-28 (ndtvprofit.com)
Fortis Healthcare Gets Target Price Raise From Nomura
Nomura has hiked the Price target for Fortis Healthcare from Rs 700 to Rs 820. Additionally, the research firm has maintained its 'buy' rating. "The India hospitals sector has significantly re-rated over the past five years, and valuations in general for the sector are rich, in our view", stated Nomura.
Read more
2025-05-26 (marketscreener.com)
Nomura Upgrades Makita to Buy from Neutral; Price Target is 5,700 Yen |
Makita has an average rating of overweight and mean price target of 5,450.83 yen, according to analysts polled by FactSet. ...
Read more
2025-05-26 (businessupturn.com)
Stocks to watch on brokerages on May 26: Jefferies bullish on NTPC, GMR; mixed views on Ashok Leyland, JSW Steel |
On May 26, several prominent stocks are in focus today as brokerages have released updated views and target price revisions for key Indian stocks following Q4 results. Here's a look at the top calls and commentary from Nomura, Jefferies, Morgan Stanley (MS), HSBC, and Macquarie. Glenmark Pharma, GMR Airports, NTPC among key brokerage mentions Glenmark […]
Read more
2025-05-26 (businessupturn.com)
Nomura maintains 'Buy' call on GE Vernova stock with target price of Rs 2,600; sees 36% earnings CAGR through FY27 |
Nomura has reiterated its 'Buy' rating on GE Vernova with a target price of ₹2,600, following a strong Q4 performance marked by a sharp beat on orders and healthy gross margins. The brokerage believes the company's operational resilience and strong order pipeline set the stage for long-term growth. GE Vernova's Q4 EBITDA came in 38% […]
Read more
2025-05-26 (businessupturn.com)
Nomura maintains buy on Ashok Leyland, expects 15% upside, bets on demand recovery in FY26 |
Nomura has maintained its Buy rating on Ashok Leyland, assigning a target price of ₹275, which implies a 15.4% upside from the current market price of ₹238.26. The brokerage noted that Q4 EBITDA was in line with expectations, and sees growth drivers building up for FY26. Nomura expects a pickup in replacement demand, alongside improved […]
Read more
2025-05-24 (longportapp.com)
Nomura lowers Weibo's target price to $10, indicating that the advertising business seems to have bottomed out
Nomura has lowered its target price for Weibo to $10, believing that its advertising business seems to have bottomed out. Weibo's first-quarter profit exceeded expectations, with total revenue of $397 million flat, and non-GAAP operating profit rising by 3%. The guidance for the second quarter meets expectations, with total revenue expected to remain flat and non-GAAP operating profit margin between 33% and 34%. Despite changes in the market environment, the long-term outlook remains unclear, but management is slightly optimistic about the advertising outlook and maintains its full-year revenue guidance
Read more
2025-05-22 (marketbeat.com)
Nomura Holdings Inc. Buys New Shares in CF Industries Holdings, Inc. (NYSE:CF)
Nomura Holdings Inc. acquired a new position in shares of CF Industries Holdings, Inc. (NYSE:CF - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 6,069 shares of the basic materials company's stock, value
Read more
2025-05-22 (businessupturn.com)
Nomura maintains 'Buy' on Uno Minda, sees 26.7% upside; Q4 beats estimates, strong growth outlook in EV, sensors |
Nomura has reiterated a 'Buy' rating on Uno Minda Ltd, with a target price of ₹1,242, implying a 26.7% upside from the current market price of ₹980.00 (as of latest close). The brokerage noted that Q4 FY25 results were ahead of consensus estimates, supported by strong execution across segments. It highlighted that the company's ongoing […]
Read more
2025-05-22 (businessupturn.com)
Brokerages on Uno Minda stock: Buy, sell or hold? Check Nomura and Goldman call |
Nomura and Goldman Sachs have reiterated buy ratings on auto-components maker Uno Minda following its March-quarter results, highlighting robust growth visibility from premiumisation, electric-vehicle adoption and expansion into high-value segments such as ADAS sensors and controllers. Nomura kept its target price at Rs 1,242, implying a potential upside of roughly 27 percent from the current […]
Read more
2025-05-21 (businessupturn.com)
Zydus share price: Nomura sees 29% upside, upbeat on US growth and vaccine contribution |
Nomura has retained its buy rating on Zydus Lifesciences with a target price of ₹1,140, implying an upside of nearly 29% from the current market price of ₹884.45. The brokerage acknowledges a Q4 EBITDA miss but remains optimistic about FY26, citing better-than-expected guidance. The Q4 EBITDA came in below expectations, primarily due to lower contribution […]
Read more
Used by 100+ compliance teams and analysts